Literature DB >> 29708132

The evolving understanding of immunoediting and the clinical impact of immune escape.

Caroline E McCoach1,2, Trever G Bivona1,2,3.   

Abstract

Year:  2018        PMID： 29708132      PMCID： PMC5906217          DOI： 10.21037/jtd.2018.03.60

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  29 in total

1.  Cancer; a biological approach. I. The processes of control.

Authors:  M BURNET
Journal:  Br Med J       Date:  1957-04-06

2.  High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.

Authors:  Teresa Rodriguez; Rosa Méndez; Chrissy H Roberts; Francisco Ruiz-Cabello; I Anthony Dodi; Miguel Angel López Nevot; Laura Paco; Isabel Maleno; Steven G E Marsh; Graham Pawelec; Federico Garrido
Journal:  Cancer Immunol Immunother       Date:  2004-10-01       Impact factor: 6.968

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

5.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Authors:  L Girard; S Zöchbauer-Müller; A K Virmani; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

6.  The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.

Authors:  Francisco Perea; Mónica Bernal; Abel Sánchez-Palencia; Javier Carretero; Cristina Torres; Clara Bayarri; Mercedes Gómez-Morales; Federico Garrido; Francisco Ruiz-Cabello
Journal:  Int J Cancer       Date:  2016-11-07       Impact factor: 7.396

7.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

8.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

9.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

10.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307
View more
  3 in total

1.  KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.

Authors:  Rosamaria Pinto; Daniela Petriella; Rosanna Lacalamita; Michele Montrone; Annamaria Catino; Pamela Pizzutilo; Maria Antonietta Botticella; Francesco Alfredo Zito; Gabriella Del Bene; Antonia Zonno; Stefania Tommasi; Simona De Summa
Journal:  Cancers (Basel)       Date:  2019-08-09       Impact factor: 6.639

Review 2.  The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway.

Authors:  Laura Martin-Hijano; Bruno Sainz
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

Review 3.  Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells.

Authors:  Timo Burster; Fabian Gärtner; Christiane Bulach; Anuar Zhanapiya; Adrian Gihring; Uwe Knippschild
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.